関連する実験動画
薬の服用順守:心血管疾患におけるその重要性
P Michael Ho1, Chris L Bryson, John S Rumsfeld
1Denver VA Medical Center, Denver, CO, USA. michael.ho@va.gov
Circulation
|June 17, 2009
まとめ
薬物不服従は一般的であり,健康状態の悪化とコストの増加に関連しています. 患者の遵守を改善するには,測定,有病率,理由,介入の理解が必要です.
科学分野:
- 医療サービス 研究 医療サービス
- クリニック薬局 臨床薬局
- 患者アデレンスに関する研究
背景:
- 適切な投与量と治療の継続を含む薬剤の遵守は,効果的な治療に不可欠です.
- 薬物不服従は重大な課題であり,健康に悪影響を及ぼし,医療費を増加させます.
- 現在の臨床実務では,患者の薬剤服用順守を測定したり,改善のための介入を実施したりすることはめったにありません.
研究 の 目的:
- 薬の投与順守を測定するための方法を見直す.
- 薬物不服従の流行と原因を調査する.
- 非遵守と患者のアウトカムとの関連性を調査し,改善のための介入について議論する.
主な方法:
- 粘着測定技術に関する文献レビュー.
- 薬物不服従に関する流行データ分析.
- 健康上の結果に対する不服従の影響に関する研究のまとめ.
- 加入しない理由の特定された理由のレビュー.
- 薬の服用順守を高めるためのエビデンスベースの介入のまとめ.
主要な成果:
- 薬の投与順守を測定するために様々な方法が存在するが,実際での使用は限られている.
- 薬物不服従は,多様な患者集団と治療分野において一般的です.
- 不遵守は,より悪い臨床結果と,医療費の増加と強く関連しています.
- 患者関連,薬剤関連,医療システム関連の問題など,複数の要因が非遵守に寄与しています.
- 行動戦略から技術的解決策に至るまで,さまざまな介入が,薬の服用順守を改善することができます.
結論:
- 薬物不服従に対処することは,患者の治療結果を改善し,医療費を削減するために極めて重要です.
- 定期的な臨床実務において,薬物投与の順守を高めるために,体系的な測定と標的型の介入が必要である.
- 継続的な研究は,アデレンス介入の最適化と標準的なケアパスウェイへの統合に焦点を当てるべきである.
関連する概念動画
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...